TINAVI(SH:688277) Sou Hu Cai Jing·2026-01-24 17:58Core Viewpoint - Tianzhihang (688277) has shown a significant increase in stock price and market performance, indicating strong growth potential in the orthopedic surgical robot market, where it holds a leading position [1]. Group 1: Company Performance - As of January 23, 2026, Tianzhihang's stock closed at 23.99 yuan, up 4.62% from the previous week [1]. - The company reached a market capitalization of 10.939 billion yuan, ranking 36th out of 127 in the medical device sector and 1939th out of 5182 in the A-share market [1]. - On January 21, 2026, Tianzhihang recorded two block trades with a total transaction value of 4.0034 million yuan [3]. Group 2: Market Position and Growth - In 2025, the domestic market for orthopedic surgical robots is expected to see over 100 units awarded in procurement, with a year-on-year growth rate of approximately 35% [1]. - Tianzhihang maintains the largest market share in the domestic orthopedic surgical robot sector, with over 70% of the total surgical volume, translating to more than 35,000 surgeries out of 48,500 performed in the first three quarters of 2025 [1][3]. Group 3: Strategic Initiatives - The company is exploring new models such as "purchasing technology services" to reduce upfront costs for medical institutions and enhance the accessibility of surgical robots [1]. - Tianzhihang is actively pursuing international expansion by participating in overseas exhibitions and developing differentiated market strategies to enhance its global competitiveness [1]. - The company's products have received CE certification from the EU, allowing them to meet the demands of high-end markets in developed countries while also being cost-effective for developing nations [1]. Group 4: Industry Developments - The National Healthcare Security Administration has released a guideline to establish a unified pricing project for surgical and treatment auxiliary services, promoting the adoption of robotic surgical technology [2]. - The guideline aims to incentivize companies to develop high-value technologies and guide the industry towards high-quality, standardized development [2].